# Edesa Biotech, Inc.: overview EDSA · Nasdaq · CIK 1540159 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/edsa.md) · [Financials](/companies/edsa/financials.md) · [Filings](/companies/edsa/filings.md) · [Insiders](/companies/edsa/insiders.md) Latest reported revenue: [$0](/filings/0001654954-21-013551.md) for Q4 FY2021, three months to 2021-09-30, from the 10-K filed Dec 28, 2021 (XBRL us-gaap:Revenues, accession 0001654954-21-013551). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001654954-21-013551.md) | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.10)](/filings/0001654954-21-013551.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(13.7)](/filings/0001654954-22-016633.md) | [(12.3)](/filings/0001654954-23-015632.md) | [(6.6)](/filings/0001171843-24-006946.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/edsa/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Velan Capital Investment Management LP](/funds/1848809.md) | 2026-06-30 | $6.7m | 827,500 | | Unchanged | | [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $5.4m | 669,500 | | Reduced −18,000 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $4.6m | 563,239 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $4.6m | 561,751 | | New +561,751 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $3.2m | 456,439 | | Added +426,439 | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $1.7m | 205,000 | | New +205,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $665.4k | 81,839 | | Reduced −4,127 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $657.6k | 80,879 | | Added +3,825 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $589.1k | 72,465 | | Reduced −43,256 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $314.8k | 38,718 | | Added +272 | ## Recent filings [All 748 filings](/companies/edsa/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 17:24 ET | [8-K](/filings/0001171843-26-006794.md) | 5.02 Departure or appointment of officers or directors | 0001171843-26-006794 | | 2026-10-15 | 09:15 ET | [8-K](/filings/0001171843-26-006647.md) | 8.01 Other events | 0001171843-26-006647 | | 2026-08-25 | 18:00 ET | [SCHEDULE 13D/A](/filings/0001171843-26-005738.md) | Ownership report, active investor, amended | 0001171843-26-005738 | | 2026-08-25 | 16:38 ET | [SCHEDULE 13D/A](/filings/0000921895-26-002310.md) | Ownership report, active investor, amended | 0000921895-26-002310 | | 2026-08-20 | 16:15 ET | [8-K](/filings/0001171843-26-005686.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001171843-26-005686 | | 2026-08-13 | 16:40 ET | [10-Q](/filings/0001171843-26-005502.md) | Quarterly report, period 2026-06-30 | 0001171843-26-005502 | | 2026-08-13 | 16:20 ET | [8-K](/filings/0001171843-26-005499.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-005499 | | 2026-06-16 | 17:06 ET | [SCHEDULE 13D/A](/filings/0001171843-26-004153.md) | Ownership report, active investor, amended | 0001171843-26-004153 | | 2026-06-11 | 09:20 ET | [8-K](/filings/0001171843-26-004053.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001171843-26-004053 | | 2026-06-05 | 09:25 ET | [8-K](/filings/0001171843-26-003931.md) | 8.01 Other events | 0001171843-26-003931 | ## Latest annual report [Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001171843-25-007914.md), filed Dec 12, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1540159 - Tickers: EDSA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A1 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:02 ET. No prices; not investment advice.